This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Proton pump inhibitors (PPIs) such as omeprazole and lansoprazole inhibit the production of gastric acid.

They are the drugs of choice for patients with significant erosive oesophagitis and for patients with Zollinger- Ellinson syndrome.

The NICE guideline concerning the management of dyspepsia in primary care suggests PPIs as first-line therapies in non-ulcer dyspepsia, gastro-oesophageal reflux disease and peptic ulcer disease (see linked NICE dyspepsia guideline).

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.